SlideShare a Scribd company logo

Management of drug resistant tb patients

http://egchest.blogspot.com/2012/05/management-of-drug-resistant-tb.html

1 of 22
Download to read offline
Management of Drug Resistant
   Tuberculosis Patients,
     Egypt experience
Study Objective

• To evaluate the so far effect of
  treatment on the first treatment
  cohort of MDR-TB patients and
  analysing some factors that might
  affect the interim outcome.
Materials & Methods
• The pilot program had the initial approval of the
  GLC/WHO to treat 75 patients in the first DR-TB centre in
  Abbassia chest hospital for inpatient care of patients with
  MDR-TB.
• One floor of 12 rooms was chosen and modified to apply
  the necessary infection control procedures.
• Mission from the GLC in early 2003 before approval of the
  program was issued.
• This centre was assigned for the inpatients treatment while
  ambulatory treatment was conducted in TB units after the
  working staff in these units received 3 days training on
  management of those patients before they are discharged for
  ambulatory treatment.
Materials & Methods
• The national reference laboratory was chosen to do the
  initial culture and drug susceptibility testing (DST) to
  determine the resistance pattern of the patient before
  starting treatment.
• The first cohort of patients to be enrolled in the pilot
  project consisted of chronic patients found in the TBMUs
  and DSTs were done to all of them to confirm infection
  with MDR-TB.
• The frequency of patient enrolment was determined by
  the hospital capacity and availability of the drugs.
  Patients were eligible for treatment if they were proved to
  be MDR-TB with no absolute exclusion criteria.
Materials & Methods
•   Patient with concomitant diseases or with poor general condition were
    considered high risk group for close supervision and frequent evaluation.
•    A formal written consent was taken from every patient before starting
    treatment.
•   The proved MDR-TB patients were put on a treatment regimen based on
    the resistance profile of patients to first line anti-TB treatment and would
    be modified according to treatment history of the patient.
•   If the patient gave any history of previous use of the second line anti-TB
    drugs, which are not available in the market in Egypt, except for Amikacin
    and Flouroquinolones, the regimen would have been adjusted accordingly.
•    DST for second line drugs was made for patients who gave history of
    previous use of the previously mentioned second line anti-TB drugs or
    showed potential failure to prepare the retreatment regimen. Accordingly,
    the regimen used can be considered, more or less an individualized one.
Treatment regimens
• MDR-TB patients were started on a regimen consisting Kanamycin,
  Ofloxacin, Ethionamide, p-aminosalicylic acid (PAS), Cycloserine.
• Patient received the injectable drug for nine months, the first three
  months on daily basis, and then every other day. The treatment
  duration was 21 months for patients who were enrolled and
  completed treatment before the emergency update of the
  programmatic management of DR-TB guidelines were issued with
  recommendation of at least 18 months treatment after sputum
  culture conversion.
• The duration of hospitalization was about 9 months, during the use
  of an injectable drug and the clinical condition of the patient and
  tolerability of the drugs. Patients were tested for HIV at the start of
  treatment.

Recommended

JOURNAL CLUB PRESENTATION
JOURNAL CLUB PRESENTATIONJOURNAL CLUB PRESENTATION
JOURNAL CLUB PRESENTATIONpankaj rana
 
Journal club vitamin c
Journal club vitamin c Journal club vitamin c
Journal club vitamin c Yassin Alsaleh
 
JOURNAL CLUB PRESENTATION
JOURNAL CLUB PRESENTATIONJOURNAL CLUB PRESENTATION
JOURNAL CLUB PRESENTATIONKAVIYA AP
 
Journal Club presentation in Nursing Research
Journal Club presentation in Nursing ResearchJournal Club presentation in Nursing Research
Journal Club presentation in Nursing ResearchDhara Vyas
 
PEPTIC (Holden Young - Roseman University College of Pharmacy)
PEPTIC (Holden Young - Roseman University College of Pharmacy)PEPTIC (Holden Young - Roseman University College of Pharmacy)
PEPTIC (Holden Young - Roseman University College of Pharmacy)HoldenYoung3
 
PEPTIC (Holden Young - Roseman University College of Pharmacy)
PEPTIC (Holden Young - Roseman University College of Pharmacy)PEPTIC (Holden Young - Roseman University College of Pharmacy)
PEPTIC (Holden Young - Roseman University College of Pharmacy)HoldenYoung3
 

More Related Content

What's hot

Advances in induction in Acute Lymphocytic Leukemia
Advances in induction in Acute Lymphocytic LeukemiaAdvances in induction in Acute Lymphocytic Leukemia
Advances in induction in Acute Lymphocytic Leukemiaspa718
 
Journal club presentation @ Rxvichu!!
Journal club presentation @ Rxvichu!!Journal club presentation @ Rxvichu!!
Journal club presentation @ Rxvichu!!RxVichuZ
 
Nurse Staffing And Quality Of Careللطالب عامر آل الري
Nurse Staffing And  Quality Of Careللطالب عامر آل الريNurse Staffing And  Quality Of Careللطالب عامر آل الري
Nurse Staffing And Quality Of Careللطالب عامر آل الريTsega Tilahun
 
Journal Club: Current Thoughts for The Prevention & Treatment of Pressure Ulcers
Journal Club: Current Thoughts for The Prevention & Treatment of Pressure UlcersJournal Club: Current Thoughts for The Prevention & Treatment of Pressure Ulcers
Journal Club: Current Thoughts for The Prevention & Treatment of Pressure UlcersMeeran Earfan
 
Journal club presentation (chest tube) _.pptx dr shakil
Journal club presentation (chest tube) _.pptx dr shakilJournal club presentation (chest tube) _.pptx dr shakil
Journal club presentation (chest tube) _.pptx dr shakilShakil Ahmad
 
adverse events resulting in withdrawal of geologic therapy in psoriasis
adverse events resulting in withdrawal of geologic therapy in psoriasisadverse events resulting in withdrawal of geologic therapy in psoriasis
adverse events resulting in withdrawal of geologic therapy in psoriasisرازي خوري
 
Antibiotic Prophylaxis in Urology Surgery (India specific slides)
Antibiotic Prophylaxis in Urology Surgery (India specific slides)Antibiotic Prophylaxis in Urology Surgery (India specific slides)
Antibiotic Prophylaxis in Urology Surgery (India specific slides)Vijayant Govinda Gupta
 
Inbuild trial journal club
Inbuild trial  journal clubInbuild trial  journal club
Inbuild trial journal clubMidhunMohanK1
 
Journal Club Indian Journal Of Pharmacology
Journal Club Indian Journal Of PharmacologyJournal Club Indian Journal Of Pharmacology
Journal Club Indian Journal Of PharmacologyDr Ketan Asawalle
 
Corticosteroids for sore throat sr ma bmj 2018
Corticosteroids for sore throat sr ma bmj 2018Corticosteroids for sore throat sr ma bmj 2018
Corticosteroids for sore throat sr ma bmj 2018Mayra Serrano
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
PharmacoepidemiologyStanley Palma
 
Fogsi tb treatment dr vijay agrawal
Fogsi  tb treatment  dr vijay agrawalFogsi  tb treatment  dr vijay agrawal
Fogsi tb treatment dr vijay agrawalvkatbcd
 

What's hot (20)

Advances in induction in Acute Lymphocytic Leukemia
Advances in induction in Acute Lymphocytic LeukemiaAdvances in induction in Acute Lymphocytic Leukemia
Advances in induction in Acute Lymphocytic Leukemia
 
Journal club 1
Journal club 1Journal club 1
Journal club 1
 
Journal club presentation @ Rxvichu!!
Journal club presentation @ Rxvichu!!Journal club presentation @ Rxvichu!!
Journal club presentation @ Rxvichu!!
 
Nurse Staffing And Quality Of Careللطالب عامر آل الري
Nurse Staffing And  Quality Of Careللطالب عامر آل الريNurse Staffing And  Quality Of Careللطالب عامر آل الري
Nurse Staffing And Quality Of Careللطالب عامر آل الري
 
Journal Club: Current Thoughts for The Prevention & Treatment of Pressure Ulcers
Journal Club: Current Thoughts for The Prevention & Treatment of Pressure UlcersJournal Club: Current Thoughts for The Prevention & Treatment of Pressure Ulcers
Journal Club: Current Thoughts for The Prevention & Treatment of Pressure Ulcers
 
Journal club presentation
Journal club presentationJournal club presentation
Journal club presentation
 
Journal club presentation (chest tube) _.pptx dr shakil
Journal club presentation (chest tube) _.pptx dr shakilJournal club presentation (chest tube) _.pptx dr shakil
Journal club presentation (chest tube) _.pptx dr shakil
 
Journal Club: 2015 August; START study
Journal Club: 2015 August; START studyJournal Club: 2015 August; START study
Journal Club: 2015 August; START study
 
2012 vancomicina uci2012
2012 vancomicina uci20122012 vancomicina uci2012
2012 vancomicina uci2012
 
adverse events resulting in withdrawal of geologic therapy in psoriasis
adverse events resulting in withdrawal of geologic therapy in psoriasisadverse events resulting in withdrawal of geologic therapy in psoriasis
adverse events resulting in withdrawal of geologic therapy in psoriasis
 
Jc
JcJc
Jc
 
Antibiotic Prophylaxis in Urology Surgery (India specific slides)
Antibiotic Prophylaxis in Urology Surgery (India specific slides)Antibiotic Prophylaxis in Urology Surgery (India specific slides)
Antibiotic Prophylaxis in Urology Surgery (India specific slides)
 
Inbuild trial journal club
Inbuild trial  journal clubInbuild trial  journal club
Inbuild trial journal club
 
Farmakoepidemiologi3
Farmakoepidemiologi3Farmakoepidemiologi3
Farmakoepidemiologi3
 
Journal Club Indian Journal Of Pharmacology
Journal Club Indian Journal Of PharmacologyJournal Club Indian Journal Of Pharmacology
Journal Club Indian Journal Of Pharmacology
 
Corticosteroids for sore throat sr ma bmj 2018
Corticosteroids for sore throat sr ma bmj 2018Corticosteroids for sore throat sr ma bmj 2018
Corticosteroids for sore throat sr ma bmj 2018
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
 
Cohort study 123 5 sushil
Cohort study 123 5 sushilCohort study 123 5 sushil
Cohort study 123 5 sushil
 
Fogsi tb treatment dr vijay agrawal
Fogsi  tb treatment  dr vijay agrawalFogsi  tb treatment  dr vijay agrawal
Fogsi tb treatment dr vijay agrawal
 
Oral steroids in acute wheezing and asthma journal club
Oral steroids in acute wheezing and asthma journal clubOral steroids in acute wheezing and asthma journal club
Oral steroids in acute wheezing and asthma journal club
 

Viewers also liked

Viewers also liked (8)

Khornabuji
KhornabujiKhornabuji
Khornabuji
 
Khornabuji public school
Khornabuji public schoolKhornabuji public school
Khornabuji public school
 
ძველი ანაგის საჯარო სკოლის პედაგოგი
ძველი  ანაგის  საჯარო სკოლის  პედაგოგიძველი  ანაგის  საჯარო სკოლის  პედაგოგი
ძველი ანაგის საჯარო სკოლის პედაგოგი
 
恐怖的食品添物0330
恐怖的食品添物0330恐怖的食品添物0330
恐怖的食品添物0330
 
MOT
MOTMOT
MOT
 
Early detection of tuberculosis for disease management
Early detection of tuberculosis for disease managementEarly detection of tuberculosis for disease management
Early detection of tuberculosis for disease management
 
Honestidad
HonestidadHonestidad
Honestidad
 
Flashblogger
FlashbloggerFlashblogger
Flashblogger
 

Similar to Management of drug resistant tb patients

Final analysis of a trial of m72 final
Final analysis of a trial of m72 finalFinal analysis of a trial of m72 final
Final analysis of a trial of m72 finalShivaom Chaurasia
 
presentasi 19 feb 222.pptx
presentasi  19 feb 222.pptxpresentasi  19 feb 222.pptx
presentasi 19 feb 222.pptxMaelantiPermana
 
Gastroenterology Research and Practice Jan16
Gastroenterology Research and Practice Jan16Gastroenterology Research and Practice Jan16
Gastroenterology Research and Practice Jan16Lenka Kellermann
 
Linezolid for treatment of chronic XDR journal presentation
Linezolid for treatment of chronic XDR journal presentationLinezolid for treatment of chronic XDR journal presentation
Linezolid for treatment of chronic XDR journal presentationDr Momin Kashif
 
MANAGMENT OF Tubercular preventive treatment
MANAGMENT OF Tubercular preventive treatment MANAGMENT OF Tubercular preventive treatment
MANAGMENT OF Tubercular preventive treatment Kumar Utsav
 
Immune-based Therapies: A Focus on Access
Immune-based Therapies: A Focus on AccessImmune-based Therapies: A Focus on Access
Immune-based Therapies: A Focus on Accessflasco_org
 
what is new in tuberculosis
what is new in tuberculosiswhat is new in tuberculosis
what is new in tuberculosisPathKind Labs
 
Homeopathic treatment of elderly patients - a prospective observational study...
Homeopathic treatment of elderly patients - a prospective observational study...Homeopathic treatment of elderly patients - a prospective observational study...
Homeopathic treatment of elderly patients - a prospective observational study...home
 
18 march what is new in tuberculosis
18 march what is new in tuberculosis18 march what is new in tuberculosis
18 march what is new in tuberculosisPathKind Labs
 
The Efficacy and Safety of Sunitinib in Patients With Advanced Well‑Different...
The Efficacy and Safety of Sunitinib in Patients With Advanced Well‑Different...The Efficacy and Safety of Sunitinib in Patients With Advanced Well‑Different...
The Efficacy and Safety of Sunitinib in Patients With Advanced Well‑Different...Prof. Eric Raymond Oncologie Medicale
 

Similar to Management of drug resistant tb patients (20)

feb 222.pptx
feb 222.pptxfeb 222.pptx
feb 222.pptx
 
Final analysis of a trial of m72 final
Final analysis of a trial of m72 finalFinal analysis of a trial of m72 final
Final analysis of a trial of m72 final
 
Journal club
Journal clubJournal club
Journal club
 
Jornal club pancreas
Jornal club pancreasJornal club pancreas
Jornal club pancreas
 
presentasi 19 feb 222.pptx
presentasi  19 feb 222.pptxpresentasi  19 feb 222.pptx
presentasi 19 feb 222.pptx
 
Gastroenterology Research and Practice Jan16
Gastroenterology Research and Practice Jan16Gastroenterology Research and Practice Jan16
Gastroenterology Research and Practice Jan16
 
feb 22.pptx
feb 22.pptxfeb 22.pptx
feb 22.pptx
 
Hodgkins disease trial 11
Hodgkins disease trial 11Hodgkins disease trial 11
Hodgkins disease trial 11
 
Linezolid for treatment of chronic XDR journal presentation
Linezolid for treatment of chronic XDR journal presentationLinezolid for treatment of chronic XDR journal presentation
Linezolid for treatment of chronic XDR journal presentation
 
MANAGMENT OF Tubercular preventive treatment
MANAGMENT OF Tubercular preventive treatment MANAGMENT OF Tubercular preventive treatment
MANAGMENT OF Tubercular preventive treatment
 
Immune-based Therapies: A Focus on Access
Immune-based Therapies: A Focus on AccessImmune-based Therapies: A Focus on Access
Immune-based Therapies: A Focus on Access
 
what is new in tuberculosis
what is new in tuberculosiswhat is new in tuberculosis
what is new in tuberculosis
 
Rntcp
Rntcp  Rntcp
Rntcp
 
Homeopathic treatment of elderly patients - a prospective observational study...
Homeopathic treatment of elderly patients - a prospective observational study...Homeopathic treatment of elderly patients - a prospective observational study...
Homeopathic treatment of elderly patients - a prospective observational study...
 
18 march what is new in tuberculosis
18 march what is new in tuberculosis18 march what is new in tuberculosis
18 march what is new in tuberculosis
 
ISPOR poster
ISPOR posterISPOR poster
ISPOR poster
 
MDR.pptx
MDR.pptxMDR.pptx
MDR.pptx
 
The Efficacy and Safety of Sunitinib in Patients With Advanced Well‑Different...
The Efficacy and Safety of Sunitinib in Patients With Advanced Well‑Different...The Efficacy and Safety of Sunitinib in Patients With Advanced Well‑Different...
The Efficacy and Safety of Sunitinib in Patients With Advanced Well‑Different...
 
Journal ribo
Journal ribo Journal ribo
Journal ribo
 
MonarchE
MonarchE MonarchE
MonarchE
 

More from Bassem Matta

Graves Gilbert Clinic
Graves Gilbert ClinicGraves Gilbert Clinic
Graves Gilbert ClinicBassem Matta
 
سفر زكريا النبي
سفر زكريا النبيسفر زكريا النبي
سفر زكريا النبيBassem Matta
 
ٌبِدَعٌ حَدِيثَة
ٌبِدَعٌ حَدِيثَةٌبِدَعٌ حَدِيثَة
ٌبِدَعٌ حَدِيثَةBassem Matta
 
Chronology Of The Four Gospels
Chronology Of The Four GospelsChronology Of The Four Gospels
Chronology Of The Four GospelsBassem Matta
 
الأنبياء الصغار الإثنى عشر
الأنبياء الصغار الإثنى عشرالأنبياء الصغار الإثنى عشر
الأنبياء الصغار الإثنى عشرBassem Matta
 
سفر أشعياء
سفر أشعياء  سفر أشعياء
سفر أشعياء Bassem Matta
 
Personal Healthcare
Personal HealthcarePersonal Healthcare
Personal HealthcareBassem Matta
 
كتاب المزامير الشريف
كتاب المزامير الشريف كتاب المزامير الشريف
كتاب المزامير الشريف Bassem Matta
 
سفر الخروج
سفر الخروجسفر الخروج
سفر الخروجBassem Matta
 
سفر التكوين
سفر التكوينسفر التكوين
سفر التكوينBassem Matta
 
Help Jehovah Witnesses
Help Jehovah WitnessesHelp Jehovah Witnesses
Help Jehovah WitnessesBassem Matta
 
ساعد شهود يهوه
ساعد شهود يهوه ساعد شهود يهوه
ساعد شهود يهوه Bassem Matta
 

More from Bassem Matta (20)

Coptic Ruth
Coptic RuthCoptic Ruth
Coptic Ruth
 
Coptic Judges
Coptic JudgesCoptic Judges
Coptic Judges
 
Coptic Jonah
Coptic JonahCoptic Jonah
Coptic Jonah
 
Coptic Genesis
Coptic GenesisCoptic Genesis
Coptic Genesis
 
Coptic Torah
Coptic TorahCoptic Torah
Coptic Torah
 
Coptic Bible
Coptic BibleCoptic Bible
Coptic Bible
 
Graves Gilbert Clinic
Graves Gilbert ClinicGraves Gilbert Clinic
Graves Gilbert Clinic
 
سفر زكريا النبي
سفر زكريا النبيسفر زكريا النبي
سفر زكريا النبي
 
ٌبِدَعٌ حَدِيثَة
ٌبِدَعٌ حَدِيثَةٌبِدَعٌ حَدِيثَة
ٌبِدَعٌ حَدِيثَة
 
Chronology Of The Four Gospels
Chronology Of The Four GospelsChronology Of The Four Gospels
Chronology Of The Four Gospels
 
الأنبياء الصغار الإثنى عشر
الأنبياء الصغار الإثنى عشرالأنبياء الصغار الإثنى عشر
الأنبياء الصغار الإثنى عشر
 
سفر أشعياء
سفر أشعياء  سفر أشعياء
سفر أشعياء
 
Personal Healthcare
Personal HealthcarePersonal Healthcare
Personal Healthcare
 
كتاب المزامير الشريف
كتاب المزامير الشريف كتاب المزامير الشريف
كتاب المزامير الشريف
 
The Priesthood
The PriesthoodThe Priesthood
The Priesthood
 
Septuagint LXX
Septuagint LXXSeptuagint LXX
Septuagint LXX
 
سفر الخروج
سفر الخروجسفر الخروج
سفر الخروج
 
سفر التكوين
سفر التكوينسفر التكوين
سفر التكوين
 
Help Jehovah Witnesses
Help Jehovah WitnessesHelp Jehovah Witnesses
Help Jehovah Witnesses
 
ساعد شهود يهوه
ساعد شهود يهوه ساعد شهود يهوه
ساعد شهود يهوه
 

Recently uploaded

Biochemistry of Carbohydrates for MBBS, BDS, Lab Med 2024.pptx
Biochemistry of Carbohydrates for MBBS, BDS, Lab Med 2024.pptxBiochemistry of Carbohydrates for MBBS, BDS, Lab Med 2024.pptx
Biochemistry of Carbohydrates for MBBS, BDS, Lab Med 2024.pptxRajendra Dev Bhatt
 
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, PrayagrajPoliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
Fetal and Neonatal Physiology - Dr Faiza.pdf
Fetal and Neonatal Physiology - Dr Faiza.pdfFetal and Neonatal Physiology - Dr Faiza.pdf
Fetal and Neonatal Physiology - Dr Faiza.pdfMedicoseAcademics
 
Vertigo and Nystagmus - Clinical approach part-2.pptx
Vertigo and Nystagmus - Clinical approach part-2.pptxVertigo and Nystagmus - Clinical approach part-2.pptx
Vertigo and Nystagmus - Clinical approach part-2.pptxYasser Alzainy
 
Hydrocele and tumors of testis Introduction.pptx
Hydrocele and tumors of testis Introduction.pptxHydrocele and tumors of testis Introduction.pptx
Hydrocele and tumors of testis Introduction.pptxSizan Thapa
 
Influenza.pptx Department of Physiotherapy, SHUATS, Prayagraj
Influenza.pptx Department of Physiotherapy, SHUATS, PrayagrajInfluenza.pptx Department of Physiotherapy, SHUATS, Prayagraj
Influenza.pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...semualkaira
 
Psychedelic Interventions for Neurological Conditions [NAN 2022 Poster]
Psychedelic Interventions for Neurological Conditions [NAN 2022 Poster]Psychedelic Interventions for Neurological Conditions [NAN 2022 Poster]
Psychedelic Interventions for Neurological Conditions [NAN 2022 Poster]Brian Peacock
 
Bioavailability & Bioequivalence Studies- Definitions, Methods of Measureme...
Bioavailability & Bioequivalence  Studies- Definitions, Methods  of Measureme...Bioavailability & Bioequivalence  Studies- Definitions, Methods  of Measureme...
Bioavailability & Bioequivalence Studies- Definitions, Methods of Measureme...Rajshri
 
Finger Clubbing by Dr. Samuel2 Alawode.pptx
Finger Clubbing by Dr. Samuel2 Alawode.pptxFinger Clubbing by Dr. Samuel2 Alawode.pptx
Finger Clubbing by Dr. Samuel2 Alawode.pptxAlawode Samuel2
 
Staphylococcus.ppt.........ali.rasool.badr
Staphylococcus.ppt.........ali.rasool.badrStaphylococcus.ppt.........ali.rasool.badr
Staphylococcus.ppt.........ali.rasool.badrssuser06f49d
 
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptxArtificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptxDr. Dheeraj Kumar
 
Anatomy of Female Reproductive System.pptx
Anatomy of Female Reproductive System.pptxAnatomy of Female Reproductive System.pptx
Anatomy of Female Reproductive System.pptxMathew Joseph
 
Psychedelic Treatment Planning: Opportunities in Integrated Care
Psychedelic Treatment Planning: Opportunities in Integrated CarePsychedelic Treatment Planning: Opportunities in Integrated Care
Psychedelic Treatment Planning: Opportunities in Integrated CareBrian Peacock
 
Shodhanagha snehapana.pptx Dr Akshay Shetty
Shodhanagha snehapana.pptx Dr Akshay ShettyShodhanagha snehapana.pptx Dr Akshay Shetty
Shodhanagha snehapana.pptx Dr Akshay ShettyAkshay Shetty
 
PTERYGIUM ,clinical picture and its management.pptx
PTERYGIUM ,clinical picture and its management.pptxPTERYGIUM ,clinical picture and its management.pptx
PTERYGIUM ,clinical picture and its management.pptxvideosfildr
 
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICSPAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICSDr.Shrikrushna Sobaji
 

Recently uploaded (20)

Biochemistry of Carbohydrates for MBBS, BDS, Lab Med 2024.pptx
Biochemistry of Carbohydrates for MBBS, BDS, Lab Med 2024.pptxBiochemistry of Carbohydrates for MBBS, BDS, Lab Med 2024.pptx
Biochemistry of Carbohydrates for MBBS, BDS, Lab Med 2024.pptx
 
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, PrayagrajPoliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
 
Fetal and Neonatal Physiology - Dr Faiza.pdf
Fetal and Neonatal Physiology - Dr Faiza.pdfFetal and Neonatal Physiology - Dr Faiza.pdf
Fetal and Neonatal Physiology - Dr Faiza.pdf
 
Vertigo and Nystagmus - Clinical approach part-2.pptx
Vertigo and Nystagmus - Clinical approach part-2.pptxVertigo and Nystagmus - Clinical approach part-2.pptx
Vertigo and Nystagmus - Clinical approach part-2.pptx
 
A Comprehensive Fatty Liver Program .pptx
A Comprehensive Fatty Liver Program .pptxA Comprehensive Fatty Liver Program .pptx
A Comprehensive Fatty Liver Program .pptx
 
Hydrocele and tumors of testis Introduction.pptx
Hydrocele and tumors of testis Introduction.pptxHydrocele and tumors of testis Introduction.pptx
Hydrocele and tumors of testis Introduction.pptx
 
Influenza.pptx Department of Physiotherapy, SHUATS, Prayagraj
Influenza.pptx Department of Physiotherapy, SHUATS, PrayagrajInfluenza.pptx Department of Physiotherapy, SHUATS, Prayagraj
Influenza.pptx Department of Physiotherapy, SHUATS, Prayagraj
 
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...
 
Psychedelic Interventions for Neurological Conditions [NAN 2022 Poster]
Psychedelic Interventions for Neurological Conditions [NAN 2022 Poster]Psychedelic Interventions for Neurological Conditions [NAN 2022 Poster]
Psychedelic Interventions for Neurological Conditions [NAN 2022 Poster]
 
Bioavailability & Bioequivalence Studies- Definitions, Methods of Measureme...
Bioavailability & Bioequivalence  Studies- Definitions, Methods  of Measureme...Bioavailability & Bioequivalence  Studies- Definitions, Methods  of Measureme...
Bioavailability & Bioequivalence Studies- Definitions, Methods of Measureme...
 
eye disorders .pptx
eye disorders .pptxeye disorders .pptx
eye disorders .pptx
 
Finger Clubbing by Dr. Samuel2 Alawode.pptx
Finger Clubbing by Dr. Samuel2 Alawode.pptxFinger Clubbing by Dr. Samuel2 Alawode.pptx
Finger Clubbing by Dr. Samuel2 Alawode.pptx
 
Staphylococcus.ppt.........ali.rasool.badr
Staphylococcus.ppt.........ali.rasool.badrStaphylococcus.ppt.........ali.rasool.badr
Staphylococcus.ppt.........ali.rasool.badr
 
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
 
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptxArtificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
 
Anatomy of Female Reproductive System.pptx
Anatomy of Female Reproductive System.pptxAnatomy of Female Reproductive System.pptx
Anatomy of Female Reproductive System.pptx
 
Psychedelic Treatment Planning: Opportunities in Integrated Care
Psychedelic Treatment Planning: Opportunities in Integrated CarePsychedelic Treatment Planning: Opportunities in Integrated Care
Psychedelic Treatment Planning: Opportunities in Integrated Care
 
Shodhanagha snehapana.pptx Dr Akshay Shetty
Shodhanagha snehapana.pptx Dr Akshay ShettyShodhanagha snehapana.pptx Dr Akshay Shetty
Shodhanagha snehapana.pptx Dr Akshay Shetty
 
PTERYGIUM ,clinical picture and its management.pptx
PTERYGIUM ,clinical picture and its management.pptxPTERYGIUM ,clinical picture and its management.pptx
PTERYGIUM ,clinical picture and its management.pptx
 
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICSPAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
 

Management of drug resistant tb patients

  • 1. Management of Drug Resistant Tuberculosis Patients, Egypt experience
  • 2. Study Objective • To evaluate the so far effect of treatment on the first treatment cohort of MDR-TB patients and analysing some factors that might affect the interim outcome.
  • 3. Materials & Methods • The pilot program had the initial approval of the GLC/WHO to treat 75 patients in the first DR-TB centre in Abbassia chest hospital for inpatient care of patients with MDR-TB. • One floor of 12 rooms was chosen and modified to apply the necessary infection control procedures. • Mission from the GLC in early 2003 before approval of the program was issued. • This centre was assigned for the inpatients treatment while ambulatory treatment was conducted in TB units after the working staff in these units received 3 days training on management of those patients before they are discharged for ambulatory treatment.
  • 4. Materials & Methods • The national reference laboratory was chosen to do the initial culture and drug susceptibility testing (DST) to determine the resistance pattern of the patient before starting treatment. • The first cohort of patients to be enrolled in the pilot project consisted of chronic patients found in the TBMUs and DSTs were done to all of them to confirm infection with MDR-TB. • The frequency of patient enrolment was determined by the hospital capacity and availability of the drugs. Patients were eligible for treatment if they were proved to be MDR-TB with no absolute exclusion criteria.
  • 5. Materials & Methods • Patient with concomitant diseases or with poor general condition were considered high risk group for close supervision and frequent evaluation. • A formal written consent was taken from every patient before starting treatment. • The proved MDR-TB patients were put on a treatment regimen based on the resistance profile of patients to first line anti-TB treatment and would be modified according to treatment history of the patient. • If the patient gave any history of previous use of the second line anti-TB drugs, which are not available in the market in Egypt, except for Amikacin and Flouroquinolones, the regimen would have been adjusted accordingly. • DST for second line drugs was made for patients who gave history of previous use of the previously mentioned second line anti-TB drugs or showed potential failure to prepare the retreatment regimen. Accordingly, the regimen used can be considered, more or less an individualized one.
  • 6. Treatment regimens • MDR-TB patients were started on a regimen consisting Kanamycin, Ofloxacin, Ethionamide, p-aminosalicylic acid (PAS), Cycloserine. • Patient received the injectable drug for nine months, the first three months on daily basis, and then every other day. The treatment duration was 21 months for patients who were enrolled and completed treatment before the emergency update of the programmatic management of DR-TB guidelines were issued with recommendation of at least 18 months treatment after sputum culture conversion. • The duration of hospitalization was about 9 months, during the use of an injectable drug and the clinical condition of the patient and tolerability of the drugs. Patients were tested for HIV at the start of treatment.
  • 7. Treatment regimens • Sputum smear and culture were conducted monthly, and, when culture positive • Chest radiographs were performed at enrolment, and every 6 months thereafter • Adverse events were managed rapidly and aggressively with the ancillary drugs and with the help of specialists like a psychiatrist, without permanent removal of a drug from the treatment regimen for any patient of the study cohort. • All treatment doses of drugs were directly observed during the hospitalization period, and three times a week after discharge during the ambulatory treatment period. • Resection surgery was undertaken for one of the patients who declared failed and he is now on retreatment as after failure of second-line anti-TB treatment and not included in this analysis after surgery
  • 8. Laboratory testing • Sputum smear microscopy, culture and were conducted according to international standards in Abbassia chest hospital laboratory but DST was conducted only in the national reference laboratory. Smears were assessed using direct microscopy and culture using Lowenstein-Jensen media. • DST was conducted for 4 first-line drugs (isoniazid, rifampicin, ethambutol, streptomycin) and second- line drugs (Capreomycin, Kanamyin, Ofloxacin)
  • 9. Data collection and analysis • A computerized medical record system, Excel based, was instituted from the start of the pilot program. • This system was designed to record significantly more information than that routinely collected in the DOT program, where patient data from the entire treatment course were recorded on a single, two-sided treatment card. • Analyses were performed using SPSS (SPSS version 16.0)
  • 10. Results - Description of the studied group: - • Among the multi-drug resistant (MDR) patients (n=168) admitted to Abbassia Chest Hospital till 30/6/2009 only 65 patients completed their treatment course. • Their age ranges from 17 to 76 years with the mean = 37.8 ± 12.4 years. Male to female ratio is 46 (70.8 %) to 19 (29.2 %). No statistically significant difference between males and females as regards their mean age (t-test = 1.2, p > 0.05) • All of the patients were pulmonary tuberculosis except for 1 extra- pulmonary (cervical Pott's); 3 (4.6 %) were new cases and 62 (95.4 %) retreated cases.
  • 11. Results • The number of treatment courses taken before starting second-line treatment ranged from 1 to more than 7 with the median = 3 and mode = 2 courses. • As regards the resistance pattern: - 51 (78.5 %) patients were resistant to the four first-line drugs hence, they received the treatment regimen I (36 males and 15 females). 13 (20.0 %) patients were resistant to three of them and on treatment regimen II (9 males and 4 female). There is one (1.5 %) male patient resistant to 2 drugs (RH) and on regimen III. Resistance pattern was not significantly different between males and females (Chi- Square = 0.4, p>0.05). • 12 (18.5 %) patients (10 males and 2 female) gave positive history of receiving the second line anti-tuberculosis drugs (Ofloxacin and Amikacin in addition to one Sudanese male patient received all second line drugs) and 53 (81.5 %) patients (36 male and 17 females) denied their use. The sex difference was not statistically significant (Fisher’s Exact test, p>0.05).
  • 12. Results • The duration of TB illness before starting treatment with the second line anti-tuberculosis drugs, it was found that the mean duration = 7.3 ± 6.1 and the median = 6 years • Co-morbidity: - 12 (18.5 %) patients were found to be diabetic (6 males and 6 female) and only 2 (3.1 %) male patient was HCV positive. No statistically significant sex differences were observed for both variables (Fisher’s Exact test, p > 0.05). • There were no HIV positive cases.
  • 13. Distribution of patients according to the time taken for sputum smear to be converted negative
  • 14. Distribution of patients according to the time taken for sputum culture to be converted negative
  • 16. Treatment outcome of the studied patients
  • 17. • Some factors that might affect treatment outcome were studied. Of them the following showed significant association with successful treatment: - young age of patients, - non smoking, - no past history of intake of the second-line anti-tuberculosis drugs, - the extension of lung tissue destruction on x-ray findings and - the sputum culture conversion within 3 months of treatment. more than half of the total patients and about 83% of those achieved successful outcome were converted culture negative within the first 3 months of treatment. These factors could be taken as parameters to predict a successful outcome
  • 18. • Alcoholism and smoking are among the factors that might contribute to the development of drug resistance and hence, the unsuccessful outcome. The difference in the rate of treatment success was significant with smoking but did not reach the statistical significance among the alcohol or drug users most probably because of the small number of this group of patients. • The clearly observed high mortality rate (about 17%) could be due to that 52.3 % of the cases (34 patients out of the 65) showed extensive unilateral or bilateral lung tissue destruction, and of those who died this proportion was 90.9% ,10 out of 11 patients.
  • 19. Conclusion • About 68 % treatment success is achieved with the first group of MDR-TB cases admitted to Abbassia chest hospital. • The proportion of failures, defaulters and deaths were 9, 6, and 17% respectively. These rate that are comparable with the average treatment success rate reached within the GLC projects and with other reported literatures.
  • 20. • The high mortality rate (about 17%) highlighted the importance of continuing the ongoing efforts for the rapid diagnosis and treatment of MDR patients and the urgency of applying the direct observation throughout the whole treatment period. • The significant risk factors for successful outcome included young age of patients, non smoking, and the factors related to treatment which are the most important factors. These are negative history of intake of 2nd line anti-tuberculosis drugs, no cavity in x-ray findings and sputum culture conversion before 3 months of treatment.
  • 21. Recommendations • Decrease the inefficient and unnecessary use of the second-line anti-TB drugs (aminoglycosides&floroquinolones). • Encouragement of the application of direct observation for MDR TB patients throughout their treatment period. • Application of rapid diagnostic techniques for prompt enrollment of patients in the correct treatment regimen. • Strong patient support and follow up system is mandatory to achieve better results especially with MDR TB patients
  • 22. Limitations • The effect of surgical intervention on the treatment outcome of MDR TB patients was not investigated as this treatment modality was not performed widely enough with our patients to evaluate its role. • More data from high risk patients is needed for better evaluation of treatment especially those with diabetes, HCV and HIV infections.

Editor's Notes

  1. After three months, about 78.5 % of the patients were converted smear negative. The rest of the 65 patients were as follows: two failed to convert (3.1%), two died before conversion (3.1%), one defaulted, one was extra-pulmonary and one was pulmonary smear negative.
  2. * These cases include 5 patients died before culture conversion and 6 cases failed treatment.